Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Buy" from Brokerages

Key Points

• Dyne Therapeutics, Inc. has received an average rating of "Buy" from sixteen brokerages, with the average 12-month price target set at $34.06.
• CEO John Cox recently acquired 100,000 shares of Dyne Therapeutics at an average cost of $9.11 per share, significantly increasing his ownership stake in the company.
• Institutional investors own 96.68% of Dyne Therapeutics' stock, with notable increases from firms like Hsbc Holdings and Comerica Bank during the fourth quarter.

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have been given an average rating of "Buy" by the sixteen brokerages that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $34.0667.

Several brokerages have recently commented on DYN. Evercore ISI reaffirmed an "outperform" rating on shares of Dyne Therapeutics in a research note on Friday, July 11th. Robert W. Baird lowered their price target on Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating for the company in a research report on Wednesday, June 18th. Raymond James Financial upgraded Dyne Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their price objective for the stock from $31.00 to $35.00 in a report on Monday, August 25th. Sanford C. Bernstein started coverage on Dyne Therapeutics in a research report on Tuesday, June 24th. They issued a "market perform" rating and a $13.00 price objective on the stock. Finally, Stifel Nicolaus decreased their target price on Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating for the company in a report on Thursday, July 31st.

Insider Transactions at Dyne Therapeutics

In related news, CEO John Cox acquired 100,000 shares of the firm's stock in a transaction on Monday, July 14th. The stock was acquired at an average cost of $9.11 per share, for a total transaction of $911,000.00. Following the acquisition, the chief executive officer owned 242,179 shares of the company's stock, valued at $2,206,250.69. This trade represents a 70.33% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 14.14% of the company's stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds have recently made changes to their positions in DYN. Hsbc Holdings PLC raised its holdings in Dyne Therapeutics by 45.5% in the fourth quarter. Hsbc Holdings PLC now owns 13,354 shares of the company's stock worth $316,000 after purchasing an additional 4,178 shares in the last quarter. Northern Trust Corp grew its position in shares of Dyne Therapeutics by 7.7% in the 4th quarter. Northern Trust Corp now owns 777,013 shares of the company's stock worth $18,306,000 after buying an additional 55,511 shares during the period. Comerica Bank increased its stake in shares of Dyne Therapeutics by 20,133.7% in the 4th quarter. Comerica Bank now owns 35,409 shares of the company's stock worth $834,000 after acquiring an additional 35,234 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of Dyne Therapeutics by 3.2% in the 4th quarter. Ameriprise Financial Inc. now owns 219,635 shares of the company's stock worth $5,175,000 after acquiring an additional 6,735 shares in the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in Dyne Therapeutics during the 4th quarter valued at about $1,578,000. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Stock Performance

NASDAQ:DYN opened at $14.22 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 16.83 and a current ratio of 16.83. Dyne Therapeutics has a fifty-two week low of $6.36 and a fifty-two week high of $37.08. The firm has a market cap of $2.02 billion, a PE ratio of -3.68 and a beta of 1.10. The business has a 50 day moving average price of $10.79 and a 200-day moving average price of $11.16.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Monday, July 28th. The company reported ($0.97) EPS for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02. Equities research analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.